Business
CSL profits boom 45pc as flu business soars – The Australian Financial Review
The blood products giant notched up its fastest profit and revenue growth in recent years despite a uniquely challenging first half.
Sales of CSLs Hizentra product grew strongly, up 19 per cent, reflecting the benefits of home administration and the continued strong uptake for the treatment of the debilitating neurological disorder CIDP (chronic inflammatory demyelinating polyneuropathy).
The company declared a dividend of $US1.04 per share, up 9 per cent.
Guidance maintained
Despite the strong growth in the first half, the company maintained its full-year guidance of net profit of $US2.17 billion to $US2.265 billion at constant…
-
Noosa News23 hours agoTwo-time Archibald Prize-winning painter William Robinson has died, aged 89
-
Noosa News23 hours agoWilliam Robinson dies aged 89
-
General23 hours agoCalls for corruption probe into completion of mayor’s Surfers Paradise Bowls Club site purchase
-
General23 hours agoMatt Wright wanted to hinder investigations into chopper crash ‘at almost any cost’, jury hears